bearish
Junshi Bioscience Lock-Up Expiry: Valuation Still Rich with Few R&D Updates
405 Views24 Jun 2019 17:04
Shanghai Junshi Bioscience Co. Ltd. (1877 HK) was listed on December 2018 and recorded a stellar debut performance thanks to the NDA approval for...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- 3SBio Inc (1530.HK) - The Concerns and the Outlook29 Jun 2021
- Industry Report - Insights on Hair Loss Prevention and Hair Growth Industry17 Jun 2021
- Junshi Bio (君实医药) Placement - Expected Deal but Large Deal Size15 Jun 2021
- Junshi Bioscience Lock-Up Expiry: Valuation Still Rich with Few R&D Updates24 Jun 2019
- Junshi Bioscience (君实医药) IPO: Rich Valuation, but Catalyst Ahead11 Dec 2018
- Junshi Bioscience (君实医药) IPO: Thoughts on Valuation (Part 2)03 Dec 2018
x